Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 19/20 | 1.00 |
| ▸ | BRD1 | O95696 | 10/20 | 1.00 |
| ▸ | BRPF3 | Q9ULD4 | 9/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 1.00 |
| ▸ | BRD4 | O60885 | 5/20 | 1.00 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 1.00 |
| ▸ | TRIM24 | O15164 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823517 | 1.00 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL23318384 | 0.90 | BRPF1 (0.82) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560647 | 0.89 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560663 | 0.87 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560703 | 0.84 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL14722196 | 0.83 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17576473 | 0.82 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560705 | 0.82 | BRPF1 (0.70) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560691 | 0.81 | BRPF1 (0.89) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560713 | 0.81 | BRPF1 (0.86) | BRPF1BRD1BRPF3BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | BRPF1 469/4885BRD1 1579/4885BRPF3 664/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | BRPF1 1129/4885BRD1 203/4885BRPF3 14/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | BRPF1 1129/4885BRD1 203/4885BRPF3 14/4885 |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRPF1 104/4885BRD1 4/4885BRPF3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.